dose conversion semaglutide to tirzepatide Switching from dosage chart: complete guide Switching From Semaglutide To Tirzepatide

Zepbound received FDA approval in November 2023 for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity

During your consultation, we evaluate your medical history, current medications, existing health conditions, weight loss goals, and laboratory results to determine whether this treatment is appropriate

To be eligible, youll need a commercial drug insurance plan, a Mounjaro prescription for an approved use, and not to be enrolled in government-funded insurance

These trial results and Mounjaros track record among diabetes patients sets Lilly up for a promising weight loss FDA submission in the next few weeks, with an approval potentially coming by the end of 2023